<DOC>
	<DOCNO>NCT02648464</DOCNO>
	<brief_summary>This safety pilot study evaluate effect hydroxychloroquine prevent recurrent cardiovascular event among myocardial infarction patient . Half participant receive hydroxychloroquine , whereas half receive placebo six month .</brief_summary>
	<brief_title>Hydroxychloroquine Prevention Cardiovascular Events Myocardial Infarction Patients - Safety Pilot Trial</brief_title>
	<detailed_description>Anti-rheumatic medication decrease cardiovascular mortality rheumatoid arthritis patient , base mainly anti-inflammatory effect . No study address effect prevent recurrent cardiovascular event among non-rheumatic patient . In pilot phase 200 myocardial infarction patient recruit index visit study hospital . Patients randomized initial coronary angiography receive either hydroxychloroquine 300 mg day placebo six month . Patients follow 12 month four visit . Visit one doctor´s office 3 5 week day recruitment . Visit two study nurse´s office 5.5 6 month . Visit three phone interview study nurse 8.5 9.5 month . Visit four 11.5 12.5 month doctor´s office . This study evaluate safety hydroxychloroquine set myocardial infarction , whether hydroxychloroquine treatment could reduce incidence recurrent cardiovascular event among myocardial infarction patient . Furthermore , effect hydroxychloroquine cardiovascular risk factor systemic inflammation parameter study . If safety pilot study 200 patient prove successful ( i.e . major complication ) , 2500 patient recruit additional center Finland Nordic Countries . Orion Pharma provide active hydroxychloroquine tablet ( Oxiklorin ) provide assistance funding study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Patients must highsensitivity troponin CKMB upper limit normal least one follow criterion : 1 . Anginal symptom suggestive cardiac ischemia 1 . Accelerating pattern anginal pain ( episodes angina least 5 minute duration frequent , severe , long duration and/or precipitate less exertion ) . 2 . Prolonged ( &gt; 20 minute ) recurrent anginal pain rest minimal effort . 3 . Anginal pain rest minimal exertion , least 20 minute duration , occur &gt; 48 hour acute Qwave myocardial infarction . 2 . ECG criteria 1 . New , persistent transient STsegment depression &gt; 0,1 mV ( 0,08 second Jpoint ) least 2 extremity lead 3 precordial lead . 2 . New , persistent transient STsegment elevation two contiguous lead ≥0.2 mV men ≥0.15 mV woman lead V2V3 , and/or ≥0.1 mV lead . Patients enrol within 72 hour coronary angiography Contraindication hydroxychloroquine ( porphyria , psoriasis , retinopathy , hypersensitivity ) Rheumatoid arthritis rheumatic disease Significant neuropathy cause Cardiomyopathy ( diagnose onset index hospitalization ) Muscle disease ( could worsen use hydroxychloroquine ) Pregnant nursing woman , woman childbearing potential without efficient contraceptive . Angina precipitate obvious provoke factor Prolonged ECG 's correct QT interval ( &gt; 470 m ) Ongoing antibiotic therapy duration Uncontrolled severe cardiac arrhythmia result hemodynamic instability Severe hepatic failure ( alanine transaminase gammaglutamyltransferase ≥2 time normal limit international normalized ratio ( INR ) &gt; 1,5 patient use warfarin , due cardiac reason ) . Renal failure , glomerular filtration rate &lt; 50 ml/min/1,73m2 Hemoglobin &lt; 100 g/l ( possible correct transfusion ) Planned percutaneous coronary intervention ( PCI ) coronary artery bypass grafting ( CABG ) Index myocardial infarction due PCI CABG restenosis . Inability interpret STT segment change ECG ( e.g . complete leave bundle branch block pace rhythm ) Prior thrombolytic therapy ( within 12 hour ) Inability give inform consent Fulminant vomit disability give oral medication Over 80 year age Life expectancy less one year Receiving another investigational drug within 4 week prior study . ( Patients participate investigational trial 4week time period may randomize long reached primary endpoint ) . Patients medical condition , investigator 's opinion , would interfere optimal participation study produce significant risk patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>